Outlook therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Outlook therapeutics Contact Number

CONTACT Outlook Therapeutics

Just Now Outlooktherapeutics.com Get All

830 609.619

Outlook Therapeutics, Inc. 485 Route 1 South, Building F, Suite 320, Iselin, NJ 08830 609.619.3990 [email protected] Business Development and Partnering Inquiries To inquire regarding partnership opportunities with Outlook Therapeutics, please …

Website: https://outlooktherapeutics.com/contact/

Category: Contact SupportShow more

Outlook Therapeutics Crunchbase Company Profile & …

3 hours ago Crunchbase.com Get All

(609) 619-3990

Also Known As Oncobiologics. Legal Name Outlook Therapeutics, Inc. Stock Symbol NASDAQ:OTLK. Company Type For Profit. Contact Email [email protected]outlooktherapeutics.com. Phone Number (609) 619-3990. Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing

Founded: 2011
Founder: Pankaj Mohan

Website: https://www.crunchbase.com/organization/oncobiologics

Category: Contact NumberShow more

SEC Filing Outlook Therapeutics, Inc.

9 hours ago Ir.outlooktherapeutics.com Get All

Name of Issuer; Outlook Therapeutics, Inc. Street Address 1 Street Address 2; 4260 U.S. ROUTE 1: City State/Province/Country ZIP/PostalCode Phone Number of Issuer

Website: https://ir.outlooktherapeutics.com/node/8761/html

Category: Contact NumberShow more

Contact Us Axsome Therapeutics

3 hours ago Axsome.com Get All

Contact Us. AXSOME THERAPEUTICS, INC. 22 Cortlandt St., 16th floor New York, NY 10007 Phone: +1(212)332-3241 +1(212)332-3241 Fax: +1‍(‍2‍1‍2‍)‍3‍2‍0‍-‍0‍2‍4‍5 Email: [email protected]

Website: https://www.axsome.com/contact-us

Category: Contact SupportShow more

Outlook Therapeutics, Inc. (OTLK) Fields Kupka

9 hours ago Fksfirm.com Get All

Shareholder Alert: Fields Kupka & Shukurov LLP is investigating potential securities violations and breach of fiduciary duty claims involving the board of directors of Outlook Therapeutics, Inc. (NASDAQ: OTLK). If you are a shareholder of Outlook Therapeutics, Inc. and wish to receive additional information about the investigation and your rights, please fill out and submit the following

Website: https://fksfirm.com/investigation-outlook-therapeutics-inc/

Category: Contact NumberShow more

EIN 383982704 Outlook Therapeutics, Inc., Cranbury, …

8 hours ago Eintaxid.com Get All

Outlook Therapeutics, Inc. is a corporation in Cranbury, New jersey. The employer identification number (EIN) for Outlook Therapeutics, Inc. is 383982704. EIN for organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS Number. It is one of the corporates which submit 10-K filings with the SEC.

Website: https://eintaxid.com/company/383982704-outlook-therapeutics%2C-inc./

Category: Contact NumberShow more

Rgenta Therapeutics Inc. Mr E by EasyLeadz contact

7 hours ago Easyleadz.com Get All

Rgenta Therapeutics Inc. - email id & phone of 1 top management contacts like Founder, CEO, CFO, CMO, CTO, Marketing or HR or Finance head & all company details.

Website: https://www.easyleadz.com/company/rgenta-therapeutics-inc

Category: Contact SupportShow more

Outlook Therapeutics Reports Positive Efficacy and …

6 hours ago Ir.oncobiologics.com Get All

Outlook Therapeutics expects ONS-5010, if approved, to be a safe and cost-effective choice for patients, payors and clinicians worldwide for retinal indications. Outlook Therapeutics is also developing registration documents on a parallel path for approvals in Europe and expects to submit them shortly after completing the submission to the FDA.

Website: https://ir.oncobiologics.com/news-releases/news-release-details/outlook-therapeutics-reports-positive-efficacy-and-safety-data

Category: Contact NumberShow more

Outlook Therapeutics, Inc. (OTLK) Stock Forum & …

7 hours ago Finance.yahoo.com Get All

The NORSE THREE study was conducted to ensure an adequate number of patients with wet AMD and other retinal diseases had been dosed with ONS-5010 to support Outlook Therapeutics’ planned new

Website: https://finance.yahoo.com/quote/OTLK/community/

Category: Contact NumberShow more

Some Analysts Just Cut Their Outlook Therapeutics, Inc

4 hours ago Finance.yahoo.com Get All

Following the latest downgrade, the current consensus, from the five analysts covering Outlook Therapeutics, is for revenues of US$260k in 2020, …

Website: https://finance.yahoo.com/news/analysts-just-cut-outlook-therapeutics-123901687.html

Category: Contact NumberShow more

Senior Leadership Outlook Therapeutics

6 hours ago Outlooktherapeutics.com Get All

Mr. Evanson has served as our Chief Commercial Officer since November 2018. Mr. Evanson joined Outlook Therapeutics from Scott Three Consulting where he was the Founder and President. Previously he was a Managing Director in the Life Science Practice of Navigant from 2014 to 2018. He joined the firm in September of 2014 from Novartis (Alcon

Website: https://outlooktherapeutics.com/about/senior-leadership/

Category: Contact NumberShow more

A Clinical Effectiveness Study Examining the Efficacy …

1 hours ago Clinicaltrials.gov Get All

You have reached the maximum number of saved studies (100). To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Outlook Therapeutics, Inc. More Information. Go to

Website: https://www.clinicaltrials.gov/ct2/show/NCT03844074

Category: Contact NumberShow more

Outlook Therapeutics Presents Positive NORSE THREE …

2 hours ago Ir.outlooktherapeutics.com Get All

The NORSE THREE study was conducted to ensure an adequate number of patients with wet AMD and other retinal diseases had been dosed with ONS-5010 to support Outlook Therapeutics’ planned new biologics license application (BLA) submission in the United States and for other global regulatory filings. The open-label study met its goal of

Website: https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeutics-presents-positive-norse-three-safety-data

Category: Contact NumberShow more

Board of Directors Outlook Therapeutics

7 hours ago Outlooktherapeutics.com Get All

Randy Thurman Mr. Thurman has served as Executive Chairman since June 2018 and as a member of our board of directors since April 2018. Mr. Thurman is currently a senior advisor at BC Partners, a private equity firm, and is also currently a member of the Board of Directors at Allscripts, Inc. and

Website: https://outlooktherapeutics.com/about/board-of-directors/

Category: Contact NumberShow more

Outlook Therapeutics Inc. (OTLK):Buy today, is the

6 hours ago Baxterreport.com Get All

The total number of common shares currently owned by the public is 168.42 million. OTLK does have institutional investors; and they hold 12.90% of the stock. Outlook Therapeutics Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares.

Website: https://baxterreport.com/2021/09/01/outlook-therapeutics-inc-otlkbuy-today-is-the-recommendation-of-the-stocks-medium-term-indicators-2/

Category: Contact NumberShow more

Outlook Therapeutics Reports Positive Efficacy and …

2 hours ago Finance.yahoo.com Get All

Outlook Therapeutics management will host a conference call and webcast presentation for investors, analysts, and other interested parties today, Tuesday, August 3, 2021, at 8:00 a.m. ET

Website: https://finance.yahoo.com/news/outlook-therapeutics-reports-positive-efficacy-100000853.html

Category: Contact NumberShow more

Adagio Therapeutics Mr E by EasyLeadz contact …

3 hours ago Easyleadz.com Get All

Outlook Wordpress Adagio Therapeutics Head office, Adagio Therapeutics contact details and more. Where is Adagio Therapeutics headquarters? Adagio Therapeutics headquarters is in Waltham, Massachusetts, United States. Try the contact number finder tool for free,get started in seconds. No Credit Card Required.

Website: https://www.easyleadz.com/company/adagio-therapeutics

Category: Contact SupportShow more

Outlook Therapeutics Presents Positive NORSE THREE …

Just Now Finance.yahoo.com Get All

The NORSE THREE study was conducted to ensure an adequate number of patients with wet AMD and other retinal diseases had been dosed with ONS-5010 to support Outlook Therapeutics’ planned new

Website: https://finance.yahoo.com/news/outlook-therapeutics-presents-positive-norse-120500273.html

Category: Contact NumberShow more

Outlook Therapeutics Provides Clinical Update on ONS …

4 hours ago Ir.outlooktherapeutics.com Get All

“The remainder of 2020 is poised to be an exciting year for Outlook Therapeutics and ONS-5010 as we approach multiple major milestones in the coming quarter,” said Lawrence A. Kenyon, President, CEO and CFO of the Company. “The agreed-upon regulatory strategy with the FDA that includes the two registration trials provides us with a

Website: https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeutics-provides-clinical-update-ons-5010

Category: Contact NumberShow more

Outlook Therapeutics Completes Patient Enrollment for

3 hours ago Ir.outlooktherapeutics.com Get All

Due to the number of patients in screening at the time of achieving the trial’s stated goal of enrolling 220 patients in the study, Outlook Therapeutics has enrolled 227 patients at 39 clinical trial sites in the United States. Patients in the trial are being treated for 12 months.

Website: https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeutics-completes-patient-enrollment-norse-2-study

Category: Contact NumberShow more

Outlook Therapeutics to Present at the Cantor …

2 hours ago Finance.yahoo.com Get All

Live fireside chat with C. Russell Trenary, President and CEO of Outlook Therapeutics on Tuesday, September 28 at 2:00 PM ETISELIN, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) -- …

Website: https://finance.yahoo.com/news/outlook-therapeutics-present-cantor-fitzgerald-120500046.html

Category: Contact NumberShow more

Should You Buy Outlook Therapeutics Inc (OTLK) Stock …

9 hours ago Investorsobserver.com Get All

Outlook Therapeutics Inc (Outlook Therapeutics Inc ()) is higher by Monday morning, with the stock increasing 8.26% in pre-market trading to 2.36.OTLK's short-term technical score of 98 indicates that the stock has traded more bullishly over the last month than 98% of stocks on the market.

Website: https://www.investorsobserver.com/news/stock-update/should-you-buy-outlook-therapeutics-inc-otlk-stock-monday

Category: Contact NumberShow more

Outlook Therapeutics Appoints C. Russell Trenary III as

1 hours ago Ir.outlooktherapeutics.com Get All

Experienced executive with a track-record of successful eye care product launches Appointment reflects Outlook Therapeutics’ dedication to transition to commercial-stage company ISELIN, N.J. , July 07, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

Website: https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeutics-appoints-c-russell-trenary-iii-president

Category: Contact NumberShow more

Outlook Therapeutics Funding, Financials, Valuation

2 hours ago Crunchbase.com Get All

Outlook Therapeutics has raised a total of $82M in funding over 4 rounds. Their latest funding was raised on Jan 29, 2021 from a Post-IPO Equity round. Outlook Therapeutics is registered under the ticker NASDAQ:OTLK . Outlook Therapeutics is funded by 5 investors. Longwood Capital Partners and Sabby Management are the most recent investors.

Website: https://www.crunchbase.com/organization/oncobiologics/company_financials

Category: Contact NumberShow more

Premarket Mover: Outlook Therapeutics Inc (OTLK) Up …

6 hours ago Investorsobserver.com Get All

Outlook Therapeutics Inc (Outlook Therapeutics Inc ()) has risen Friday morning, with the stock climbing 22.91% in pre-market trading to 2.2.OTLK's short-term technical score of 97 indicates that the stock has traded more bullishly over the last month than 97% of stocks on the market.

Website: https://www.investorsobserver.com/news/stock-update/premarket-mover-outlook-therapeutics-inc-otlk-up-22-91

Category: Contact NumberShow more

Unmet Patient Needs Outlook Therapeutics

1 hours ago Outlooktherapeutics.com Get All

ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an Investigational Ophthalmic Formulation of Bevacizumab-vikg – with potential to address Unmet Medical and Social Needs There are unmet medical and social needs for a responsibly priced, FDA-approved ophthalmic formulation of bevacizumab to treat retinal diseases. Outlook Therapeutics is working to meet these needs. If approved and …

Website: https://outlooktherapeutics.com/pipeline/unmet-patient-needs/

Category: Contact NumberShow more

Outlook Therapeutics Presents Positive NORSE THREE …

Just Now Eyewire.news Get All

The NORSE THREE study was conducted to ensure an adequate number of patients with wet AMD and other retinal diseases had been dosed with ONS-5010 to support Outlook Therapeutics’ planned new biologics license application (BLA) submission in the United States and for other global regulatory filings.

Website: https://eyewire.news/news/outlook-therapeutics-presents-positive-norse-three-safety-data-for-lytenava-bevacizumab-vikg-at-euretina

Category: Contact NumberShow more

Should You Buy Outlook Therapeutics Inc (OTLK) Stock

2 hours ago Investorsobserver.com Get All

Outlook Therapeutics Inc has fallen 11.54% over the past month, closing at $1.22 on January 6. During this period of time, the stock fell as low as $0.94 and as high as $1.40. OTLK has an average analyst recommendation of Strong Buy. The company has an average price target of $5.00. OTLK has an Overall Score of 44.

Website: https://www.investorsobserver.com/news/stock-update/should-you-buy-outlook-therapeutics-inc-otlk-stock-wednesday

Category: Contact NumberShow more

Outlook Therapeutics Stock target price prediction …

9 hours ago Macroaxis.com Get All

The number of cover stories for Outlook Therapeutics depends on current market conditions and Outlook Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme …

Website: https://www.macroaxis.com/predict/OTLK/Outlook-Therapeutics

Category: Contact NumberShow more

Outlook Therapeutics Inc. (NASDAQ: OTLK) Posted …

4 hours ago Stocksregister.com Get All

The number of analysts that have assigned OTLK a recommendation rating is 3. Out of them, 0 rate it a Hold, while 3 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Outlook Therapeutics Inc. (OTLK) as Underweight, while 0 advise Sell.

Website: https://stocksregister.com/2021/08/09/outlook-therapeutics-inc-nasdaq-otlk-posted-95-31-gain-this-year-whats-next/

Category: Contact NumberShow more

What Do Analysts Say About Outlook Therapeutics Inc. …

3 hours ago Baxterreport.com Get All

The total number of common shares currently owned by the public is 150.73 million. OTLK does have institutional investors; and they hold 11.70% of the stock. Outlook Therapeutics Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares.

Website: https://baxterreport.com/2021/08/17/what-do-analysts-say-about-outlook-therapeutics-inc-otlk/

Category: Contact NumberShow more

Outlook Therapeutics: Not That Bright An Outlook …

Just Now Seekingalpha.com Get All

1. In wet AMD, abnormally high levels of the protein VEGF (Vascular Endothelial Growth Factor), which promotes growth of abnormal blood vessels, are secreted in the eye that can lead to vision loss. Bevacizumab, sold under the brand name Avastin, is an anti-VEGF recombinant monoclonal antibody ("mAb") that inhibits VEGF and associated angiogenic activity. Anti-VEGF therapy has become the standard-of-care treatment option within the retina community globally. ONS-5010 is an ophthalmic formulation of bevacizumab-vikg under development for the treatment of wet AMD and other retinal diseases. The candidate is currently being evaluated in the second of two registration clinical trials for wet AMD (NORSE 1 and NORSE 2). Outlook plans to submit a new Biologics License Application ("BLA") to the U.S. FDA for this ophthalmic indication under the PHSA 351(A) regulatory pathway. As there are no currently approved ophthalmic formulations of bevacizumab, clinicians use unapproved repackaged IV beva...

Website: https://seekingalpha.com/article/4389143-outlook-therapeutics-not-bright-outlook

Category: Contact NumberShow more

Can Outlook Therapeutics Inc (OTLK) Stock Rise to the …

5 hours ago Investorsobserver.com Get All

Outlook Therapeutics Inc is near the top in its sector according to InvestorsObserver. OTLK gets an overall rating of 48. That means it scores higher than 48% of stocks. Outlook Therapeutics Inc gets a 92 rank in the Healthcare sector. Healthcare is number 7 out of 11 sectors.

Website: https://www.investorsobserver.com/news/stock-update/can-outlook-therapeutics-inc-otlk-stock-rise-to-the-top-of-healthcare-sector-friday

Category: Contact NumberShow more

Why Outlook Therapeutics Stock Surged Today The …

6 hours ago Fool.com Get All

Outlook Therapeutics said the successful completion of the phase 3 trial would allow it to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in …

1. Author: Joe Tenebruso

Website: https://www.fool.com/investing/2021/08/03/why-outlook-therapeutics-stock-surged-today/

Category: Contact NumberShow more

Outlook Stock Investment (NASDAQ:OTLK) Macroaxis

7 hours ago Macroaxis.com Get All

Outlook Therapeutics is trading at 2.76 as of the 1st of September 2021. This is a 4.94 percent increase since the beginning of the trading day. The stock's last reported lowest price was 2.52. Get the latest Outlook Therapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including Outlook Stock investment advice, charts, stats and more.

Website: https://www.macroaxis.com/stock/OTLK/Outlook-Therapeutics

Category: Contact NumberShow more

Outlook Therapeutics Stock Analysis 2021 OTLK …

6 hours ago Macroaxis.com Get All

Outlook Stock Analysis Notes About 48.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.33.Outlook Therapeutics had not issued any dividends in recent years. The entity had a split on the 18th of March 2019. Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing

Website: https://www.macroaxis.com/stock-analysis/OTLK/Outlook-Therapeutics

Category: Contact NumberShow more

Outlook Therapeutics Presents Positive NORSE THREE …

3 hours ago Au.finance.yahoo.com Get All

ISELIN, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the presentation of safety data from the NORSE THREE trial evaluating ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at …

Website: https://au.finance.yahoo.com/news/outlook-therapeutics-presents-positive-norse-120500273.html

Category: Contact NumberShow more

ONS5010 Clinical Progress Outlook Therapeutics

9 hours ago Outlooktherapeutics.com Get All

Outlook Therapeutics intends to initiate NORSE FOUR, a registration clinical trial that will evaluate ONS-5010 for use in treating BRVO. Diabetic Macular Edema Outlook Therapeutics also intends to commence NORSE FIVE and NORSE SIX, two registration clinical trials to …

Website: https://outlooktherapeutics.com/lytenava-clinical-progress/

Category: Contact NumberShow more

How to buy Outlook Therapeutics stock (NASDAQ: …

3 hours ago Finder.com Get All

However Outlook Therapeutics's short interest can also be evaluated against the total number of Outlook Therapeutics shares, or, against the total number of tradable Outlook Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float").

Website: https://www.finder.com/buy-outlook-therapeutics-stock

Category: Contact NumberShow more

SEC Schedule 13D filings for Outlook Therapeutics, Inc. …

7 hours ago Sec.insider-monitor.com Get All

Recent 13D Filings for Outlook Therapeutics, Inc. (OTLK) Since 2020, there have been 14 Schedule 13D forms (beneficial ownership report) filed for the company Outlook Therapeutics, Inc. (stock symbol OTLK) by 4 beneficial owners. A schedule 13D is filed when a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.

Website: https://sec.insider-monitor.com/13D/cik/1649989

Category: Contact NumberShow more

What is Outlook Therapeutics (NASDAQ:OTLK) Stock

3 hours ago Macroaxis.com Get All

If you would invest 245.00 in Outlook Therapeutics on June 19, 2021 and sell it today you would lose (5.00) from holding Outlook Therapeutics or give up 2.04% of portfolio value over 90 days. Outlook Therapeutics is currently generating 0.0625% in daily expected returns and assumes 4.3986% risk (volatility on return distribution) over the 90 days horizon.

Website: https://www.macroaxis.com/performance/OTLK/Outlook-Therapeutics

Category: Contact NumberShow more

Outlook Therapeutics Valuation Today OTLK …

1 hours ago Macroaxis.com Get All

Outlook Therapeutics holds a recent Real Value of $2.13 per share. The prevailing price of the company is $2.76. Based on Macroaxis valuation methodology, the company appears to be overvalued.Our model determines the value of Outlook Therapeutics from analyzing the company fundamentals such as Return On Equity of (418.99) %, shares outstanding of 173.61 M, and Shares …

Website: https://www.macroaxis.com/valuation/OTLK/Outlook-Therapeutics

Category: Contact NumberShow more

Outlook Therapeutics Completes Patient Dosing in …

Just Now Eyewire.news Get All

Outlook Therapeutics reported that it has administered the final dose to the last patient enrolled in its pivotal NORSE TWO safety and efficacy study evaluating ONS-5010 (bevacizumab-vikg) for treatment of wet age-related macular degeneration (AMD). Topline data are expected to be reported for NORSE TWO in the third calendar quarter of 2021.

Website: https://eyewire.news/news/outlook-therapeutics-completes-patient-dosing-in-phase-3-norse-two-trial-for-wet-amd

Category: Contact NumberShow more

Outlook Therapeutics, Inc. (OTLK) Stock: Here’s Why It’s

9 hours ago Iwatchmarkets.com Get All

Outlook Therapeutics, Inc. (OTLK) is gaining in the market in today’s trading session. The company, focused on the biotech industry, is presently priced at $2.10 after a move up of 37.25% so far today. When it comes to biotech companies, there are a number of factors that have the potential to cause price movement in the […]

Website: https://iwatchmarkets.com/04/outlook-therapeutics-inc-otlk-stock-heres-why-its-headed-up/

Category: Contact NumberShow more

Spotlight Q&A: Outlook Therapeutics Developing …

4 hours ago Big4bio.com Get All

NOTE: Outlook Therapeutics will participate in a Virtual Investor KOL Roundtable on Thursday, October 29, 2020 at 10:00 AM ET. The Company’s executive team and Firas M. Rahhal, MD, of the UCLA Geffen School of Medicine will discuss the current market for retinal disease management and how the Company’s Phase 3 product candidate, if approved

Website: https://big4bio.com/spotlights/boston/spotlight-qa-outlook-therapeutics-developing-first-ophthalmic-formulation-of-bevacizumab-for-fda-approval/

Category: Contact NumberShow more

Digital therapeutics users worldwide by region 2025 …

Just Now Statista.com Get All

Digital therapeutics market revenues worldwide 2016-2025 Prominent digital health IPOs in the United States 2015 U.S. number of venture capital deals for oncology companies 2006-2018

Website: https://www.statista.com/statistics/1223257/number-of-digital-therapeutic-users-worldwide-by-region/

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Popular Brands

Olam
Oracle
Orix
Okta
Oneok
Omv
Orpea
Orsted
Opera
Omron